Are peptides legal in Illinois?

Can a Illinois resident get peptides by telehealth?

The Telehealth Act (225 ILCS 150) defines telehealth as the evaluation, diagnosis, or interpretation of electronically transmitted patient-specific data between a remote location and a licensed professional that generates interaction or treatment recommendations, lets a professional practice telehealth to the extent of the scope set by their licensing act, and requires the in-person standard of care. A professional treating a patient located in Illinois must be licensed or authorized to practice in Illinois, and section 49.5 of the Medical Practice Act (225 ILCS 60/49.5) separately requires a physician engaged in telemedicine with Illinois patients to hold an Illinois license. The statutes do not set a real-time video requirement for non-controlled prescriptions, but they also do not expressly approve questionnaire-only prescribing. Section 5 of the Telehealth Act defines telehealth services to include care delivered by an asynchronous store and forward system (transmission that does not require real-time interaction), e-visits, and virtual check-ins, so asynchronous care is a recognized telehealth modality, held to the in-person standard of care under section 15. Neither the Act nor the IDFPR pharmacy page addresses whether a first prescription may follow an asynchronous-only intake, and no IDFPR guidance on that point was found, so async_prescribing_allowed is left unknown. [1] [2] [3] [6]

How does the Illinois pharmacy board treat compounding?

In Illinois, pharmacy licensing and discipline are handled by the Department of Financial and Professional Regulation (IDFPR) with the State Board of Pharmacy acting in an advisory role, under the Pharmacy Practice Act (225 ILCS 85) and the rules at 68 Illinois Administrative Code Part 1330. Illinois has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Under 225 ILCS 85/16a, a nonresident pharmacy (one outside Illinois that ships, delivers, dispenses, or distributes prescription drugs into Illinois by any means, including over the internet) must be licensed by IDFPR and follow the Department's nonresident rules. Section 1330.640 (Pharmaceutical Compounding Standards) governs both sterile and nonsterile compounding by the official USP-NF (USP 47-NF 42, 2024 edition), limits dispensing of compounded drugs to valid patient-specific prescriptions except for defined nonsterile office use, and prohibits sterile compounding for office use unless the pharmacy is registered as a 503B outsourcing facility and licensed as a wholesale distributor; the former separate sterile section, 1330.670, is repealed. Section 1330.30(j) lists as unprofessional conduct dispensing or offering to dispense any drug that is not FDA approved, not in the USP-NF, and not on the FDA list of bulk drug substances that may be used in compounding. [1] [4] [5] [9]

Can you get compounded GLP-1s in Illinois?

Illinois patients using telehealth GLP-1 programs should confirm the prescriber holds an Illinois license and that the dispensing pharmacy holds an IDFPR nonresident pharmacy license. IDFPR has not issued its own GLP-1 rule, but it relays federal positions to licensees: its Pharmacy page posts FDA's July 2024 letter on adverse events with compounded semaglutide and tirzepatide, and its Spring 2025 compliance newsletter restated FDA's timelines that ended 503A enforcement discretion for compounded tirzepatide and set April 22, 2025 for semaglutide. [1] [2] [4] [8] [12]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Illinois?

Find a provider in Illinois

• Compounding pharmacies in Illinois
• Clinics in Illinois
• Telehealth providers in Illinois

Is it legal to buy research peptides in Illinois?

Only IDFPR-licensed pharmacies, including licensed nonresident pharmacies, may dispense prescription drugs to Illinois patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling and are not dispensed by a pharmacist. The Illinois Food, Drug and Cosmetic Act, 410 ILCS 620/17, separately bars any person from selling, delivering, holding for sale, or giving away a new drug unless an application for it has been approved under section 505 of the federal act, and 68 Ill. Adm. Code 1330.30(j) makes dispensing a drug that is not FDA approved, not in the USP-NF, and not on the FDA bulks list unprofessional conduct for a licensee. [4] [5] [7] [13]

Peptide-specific notes for Illinois

Frequently asked questions

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, and federal FDA guidance.